KIMS To Issue 77 Lakh Warrants Worth ₹600 Crore To Promoters; EGM Set For 9 July

Krishna Institute of Medical Sciences (KIMS) has received board approval to raise ₹600 crore by issuing warrants to its promoters and promoter group. A total of 77.02 lakh fully convertible warrants will be issued at ₹779 each, which includes a premium of ₹777 per warrant.

Holders get up to 18 months from the date of allotment to convert each warrant into one equity share of face value ₹2, in one go or multiple tranches.

Shareholders still need to approve the plan, and a meeting has been called for 9 July 2026 to vote on it.

KIMS shares were down on 15 June 2026. At 01:26 PM, the stock was trading at ₹774.85 down 1.13%.

The Breakdown

The warrants will be allotted to two promoters and one promoter group entity. Dr Abhinay Bollineni and Adwik Bollineni, both promoters, will each get 32.09 lakh warrants at a cost of ₹250 crore each. Bharas Ventures LLP, a promoter group entity, will receive 12.84 lakh warrants worth ₹100 crore.

Krishna Institute of Medical Sciences said subscribers will pay 25% of the warrant issue price at the time of allotment. The remaining 75% will become payable when the warrants are converted into equity shares.

The company added that the warrants must be exercised within 18 months. If the holders fail to do so, their entitlement will lapse and the amount already paid will be forfeited.

What Happens To Stake

If all warrants are converted, Dr Abhinay Bollineni's holding goes up from 2.36 lakh shares to 34.46 lakh shares, taking his stake to 0.84% from 0.06%.

Adwik Bollineni's share jumps from 40,640 to 32.50 lakh, with his stake rising to 0.80% from 0.01%.

Bharas Ventures, which currently owns nothing, will hold 12.84 lakh shares or 0.31% of the company after conversion.

Taken together, the promoter’s and promoter group's stake moves to 35.35% from 34.11%.

Also Read - Market Midday, 15 June 2026: Nifty, Sensex Rise Sharply As US-Iran Conflict Ends

A Quick Look At The Business

KIMS is one of the largest hospital chains in Telangana and Andhra Pradesh, specialising in tertiary and quaternary care.

The March quarter was a mixed bag. Revenue grew 34.85% year on year to ₹1,074.60 crore, but net profit dropped 58.25% to ₹42.50 crore.

Sources:

Business Standard

CNBC TV18